Esperion Therapeutics Inc. reported a 12% year-over-year increase in total revenue for the second quarter of 2025, reaching $82.4 million. The company's U.S. net product revenue grew by 42% compared to the same quarter last year, amounting to $40.3 million. This growth is attributed to a 10% increase in total retail prescription equivalents from the first quarter. The company recorded a net loss of $4.8 million for the three months ended June 30, 2025, compared to a net loss of $61.9 million in the same period in 2024. For the six months ended June 30, 2025, the net loss was $45.2 million, compared to a $0.9 million loss for the comparable period in 2024. Esperion achieved its first quarter of operating income from ongoing operations, with approximately $15.0 million in income, reflecting a significant improvement from the previous year. Esperion's financial outlook for 2025 anticipates operating expenses to be between $215 million and $235 million, including around $15 million in non-cash expenses related to stock compensation. The company expects to achieve sustainable profitability beginning in the first quarter of 2026. The company also announced settlement agreements with three ANDA filers, preventing the marketing of generic versions of NEXLETOL® (bempedoic acid) before 2040. Additionally, Esperion is expanding its efforts to improve payer dynamics and preparing for a consumer television advertising campaign.